Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
- PMID: 10619854
- PMCID: PMC382593
- DOI: 10.1172/JCI9083
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Figures
References
-
- Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta. 1997;1333:F217–F248. - PubMed
-
- Rowley JD. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243:290–293. - PubMed
-
- Heisterkamp N, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature. 1983;306:239–242. - PubMed
-
- Bartram CR, et al. Translocation of c-abl correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature. 1983;306:277–280. - PubMed
-
- Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550–554. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
